Nurix Therapeutics NRIX 深 滬
已收盤 08-07 16:00:00 美东时间
25.53
+0.310
+1.23%
華盛通- 最 高25.89
- 今 開25.27
- 成交量 72.99万股
- 最 低 25.0039
- 昨 收 25.22
- 總市值 26.50亿
- 52周最高 25.89
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 8.195
- 委 比 -46.67%
- 總股本 1.04亿
- 歷史最高 52.38
- 量 比 0.67
- 振 幅 3.51%
- 歷史最低 4.22
- 每 手 1
- 風險率 4.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nurix Therapeutics Earns $10M Milestone Payment Following Initiation Of Sanofi's Phase 1 Clinical Study Of SAR448272/NX-3911
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that it has earned a $10 million milestone payment following the initiation by its collaborator, ...
08-04 19:14
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Nurix Therapeutics and Roche have initiated a global Phase 3 trial, DAYBreak CLL-306, to compare bexobrutideg, a BTK degrader, with pirtobrutinib in relapsed/refractory CLL/SLL patients who previously received covalent BTK inhibitors. The study aims to demonstrate bexobrutideg's superiority, with primary endpoints of ORR and PFS. This marks the first Phase 3 trial for bexobrutideg, targeting a new treatment approach for CLL.
08-04 05:00
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
UBS Maintains Buy on Nurix Therapeutics, Raises Price Target to $31
UBS analyst David Dai maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $23 to $31.
07-23 02:45
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Nurix Therapeutics has entered a global collaboration with Roche to co-develop and commercialize bexobrutideg, a targeted protein degradation medicine. Under the agreement, Nurix receives $700 million upfront, with potential milestone payments up to $2.3 billion. Development costs are split 40% by Nurix and 60% by Roche. Both companies will share U.S. profits and losses, while Roche handles commercialization outside the U.S., paying Nurix royalti...
07-21 20:01
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
美股大行评级 | 潜在涨幅98.68%！DA Davidson上调Almonty Industries目标价至33美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持Almonty Industries"买入"评级，目标价从25美元升至33美元；Stifel：维持Nurix Therapeutics"买入"评级，目标价从34美元升至40美元
07-13 10:13
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $32 to $34.
07-10 18:10
Nurix Therapeutics Q2 EPS $(0.81) Misses $(0.74) Estimate, Sales $9.043M Miss $16.170M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 55.77 percent decrease over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $9.043 mil...
07-10 04:03
